Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteLixumistat (IM156), a metformin derivative, is a potent activator of AMPK that increases AMPK phosphorylation. IM156 blocks oxidative phosphorylation (OXPHOS) through the inhibition of complex I and increases apoptosis. IM156 ameliorates various types of fibrosis and inhibits tumors.
More Information Supplier PageLixumistat (IM156), a metformin derivative, is a potent activator of AMPK that increases AMPK phosphorylation. IM156 blocks oxidative phosphorylation (OXPHOS) through the inhibition of complex I and increases apoptosis. IM156 ameliorates various types of fibrosis and inhibits tumors.
More Information Supplier PageLixumistat (IM156), a metformin derivative, is a potent activator of AMPK that increases AMPK phosphorylation. IM156 blocks oxidative phosphorylation (OXPHOS) through the inhibition of complex I and increases apoptosis. IM156 ameliorates various types of fibrosis and inhibits tumors.
More Information Supplier PageLJH685 is a potent pan-RSK inhibitor with IC50 of 6 nM, 5 nM and 4 nM for RSK1, RSK2, and RSK3, respectively.
More Information Supplier PageLJH685 is a potent pan-RSK inhibitor with IC50 of 6 nM, 5 nM and 4 nM for RSK1, RSK2, and RSK3, respectively.
More Information Supplier PageLJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
More Information Supplier PageLJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
More Information Supplier PageLJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
More Information Supplier PageLJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
More Information Supplier PageLJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
More Information Supplier PageLL-37 acetate is a 37-residue, amphipathic, cathelicidin-derived peptide, which exhibits a broad spectrum of antimicrobial activity.
More Information Supplier PageLL-37 acetate is a 37-residue, amphipathic, cathelicidin-derived peptide, which exhibits a broad spectrum of antimicrobial activity.
More Information Supplier PageLL-37 acetate is a 37-residue, amphipathic, cathelicidin-derived peptide, which exhibits a broad spectrum of antimicrobial activity.
More Information Supplier PageLL37 (Human cathelicidin, Ropocamptide) is a cathelicidin-related antimicrobial peptide with potent chemotactic and immunomodulatory properties.
More Information Supplier PageLL37 (Human cathelicidin, Ropocamptide) is a cathelicidin-related antimicrobial peptide with potent chemotactic and immunomodulatory properties.
More Information Supplier PageLL37 (Human cathelicidin, Ropocamptide) is a cathelicidin-related antimicrobial peptide with potent chemotactic and immunomodulatory properties.
More Information Supplier PageLLY-283 is a novel and selective inhibitor of protein arginine methyltransferase 5 (PRMT5). LLY-283 inhibits PRMT5 enzymatic activity in vitro and in cells with IC50 of 22 nM and 25 nM, respectively. LLY-283 shows antitumor activity.
More Information Supplier PageLLY-283 is a novel and selective inhibitor of protein arginine methyltransferase 5 (PRMT5). LLY-283 inhibits PRMT5 enzymatic activity in vitro and in cells with IC50 of 22 nM and 25 nM, respectively. LLY-283 shows antitumor activity.
More Information Supplier PageLLY-283 is a novel and selective inhibitor of protein arginine methyltransferase 5 (PRMT5). LLY-283 inhibits PRMT5 enzymatic activity in vitro and in cells with IC50 of 22 nM and 25 nM, respectively. LLY-283 shows antitumor activity.
More Information Supplier PageLLY-284 is the diastereomer of LLY-283, which is a potent and selective SAM-competitive chemical probe for PRMT5. LLY-284 is much less active than LLY-283 and can be used as a negative control for LLY-283.
More Information Supplier PageLLY-284 is the diastereomer of LLY-283, which is a potent and selective SAM-competitive chemical probe for PRMT5. LLY-284 is much less active than LLY-283 and can be used as a negative control for LLY-283.
More Information Supplier PageLLY-284 is the diastereomer of LLY-283, which is a potent and selective SAM-competitive chemical probe for PRMT5. LLY-284 is much less active than LLY-283 and can be used as a negative control for LLY-283.
More Information Supplier PageLLY-507 is a cell-active, potent, and selective inhibitor of protein-lysine Methyltransferase SMYD2.
More Information Supplier PageLLY-507 is a cell-active, potent, and selective inhibitor of protein-lysine Methyltransferase SMYD2.
More Information Supplier PageLM10 is a selective tryptophan 2,3-dioxygenase (TDO) inhibitor with IC50 values of 0.62 and 2 μM for human and mouse TDO, respectively.
More Information Supplier PageLM10 is a selective tryptophan 2,3-dioxygenase (TDO) inhibitor with IC50 values of 0.62 and 2 μM for human and mouse TDO, respectively.
More Information Supplier PageLM11A-31 is a small molecule p75NTR Ligand that reverses cholinergic neurite dystrophy in alzheimer’s diseasemousemodels with mid- to late-stage disease progression.
More Information Supplier PageLM11A-31 is a small molecule p75NTR Ligand that reverses cholinergic neurite dystrophy in alzheimer’s diseasemousemodels with mid- to late-stage disease progression.
More Information Supplier PageLM22A-4 (LM 22A4) is a specific agonist of tyrosine kinase receptor B (TrkB) that reduces the development of tissue injury associated with spinal cord trauma.
More Information Supplier PageLM22B-10 is a small molecule TrkB/TrkC neurotrophin receptor co-activator, LM22B-10 selectively activates TrkB, TrkC, AKT and ERK in vivo and in vitro.
More Information Supplier PageLM22B-10 is a small molecule TrkB/TrkC neurotrophin receptor co-activator, LM22B-10 selectively activates TrkB, TrkC, AKT and ERK in vivo and in vitro.
More Information Supplier PageLMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
More Information Supplier PageLMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
More Information Supplier PageLMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
More Information Supplier PageLMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
More Information Supplier PageLMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
More Information Supplier PageLMT-28 is a novel synthetic interleukin-6 (IL-6) inhibitor that functions through direct binding to gp130.
More Information Supplier PageLMT-28 is a novel synthetic interleukin-6 (IL-6) inhibitor that functions through direct binding to gp130.
More Information Supplier PageLobaplatin (D-19466) is a third-generation platinum anti-neoplastic agent. It is a platinum complex with DNA alkylating activity.DMSO is not recommended to dissolve platinum-based drugs, which can easily lead to drug inactivation.
More Information Supplier PageLobaplatin (D-19466) is a third-generation platinum anti-neoplastic agent. It is a platinum complex with DNA alkylating activity.DMSO is not recommended to dissolve platinum-based drugs, which can easily lead to drug inactivation.
More Information Supplier PageLobeliae Chinensis Extract is extracted from Lobeliae Chinensis, which is a traditional Chinese herb widely used in the treatment of diabetes and found to have a hypoglycaemic mechanism related to the inhibition of DPP4.
More Information Supplier PageLOC14 is a potent inhibitor of protein disulfide isomerase (PDI) with EC50 of 500 nM and Kd of 62 nM, respectively.
More Information Supplier PageLOC14 is a potent inhibitor of protein disulfide isomerase (PDI) with EC50 of 500 nM and Kd of 62 nM, respectively.
More Information Supplier PageLodapolimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors, PD-1 and CD80. MW: 143.86 KD.
More Information Supplier PageLodapolimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors, PD-1 and CD80. MW: 143.86 KD.
More Information Supplier PageLodapolimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors, PD-1 and CD80. MW: 143.86 KD.
More Information Supplier PageLodelcizumab is a human monoclonal antibody targated against proprotein convertase subtilisin/kexin type 9 (PCSK9) with the potential to be used in research on hypercholesterolemia. MW: 145.66 KD.
More Information Supplier PageLodelcizumab is a human monoclonal antibody targated against proprotein convertase subtilisin/kexin type 9 (PCSK9) with the potential to be used in research on hypercholesterolemia. MW: 145.66 KD.
More Information Supplier PageLodelcizumab is a human monoclonal antibody targated against proprotein convertase subtilisin/kexin type 9 (PCSK9) with the potential to be used in research on hypercholesterolemia. MW: 145.66 KD.
More Information Supplier PageLodenafil (Hydroxyhomosildenafil) is a potent phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED).
More Information Supplier Page
